Zobrazeno 1 - 10
of 112
pro vyhledávání: '"Meagan Montesion"'
Autor:
Danyi Wang, Brian Elenbaas, Karthikeyan Murugesan, Kunal Shah, Meagan Montesion, Ioannis Gounaris, Juergen Scheuenpflug, Giuseppe Locatelli, Zheng Feng
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-14 (2023)
Abstract The DNA damage response (DDR) pathway regulates DNA repair and cell survival, and inactivating mutations in DDR genes can increase tumour mutational burden (TMB), a predictive biomarker of treatment benefit from anti-PD-1/PD-L1 immunotherapi
Externí odkaz:
https://doaj.org/article/2ded5998f24843ed9b46f8053f3b125a
Autor:
Radwa Sharaf, Dexter X. Jin, John Grady, Christine Napier, Ericka Ebot, Garrett M. Frampton, Lee A. Albacker, David M. Thomas, Meagan Montesion
Publikováno v:
npj Genomic Medicine, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract Tumor cells need to activate a telomere maintenance mechanism, enabling limitless replication. The bulk of evidence supports that sarcomas predominantly use alternative lengthening of telomeres (ALT) mechanism, commonly associated with alter
Externí odkaz:
https://doaj.org/article/392b82449b0c49749d70a0f47dafbda6
Autor:
Jessica K. Lee, Smruthy Sivakumar, Alexa B. Schrock, Russell Madison, David Fabrizio, Ole Gjoerup, Jeffrey S. Ross, Garrett M. Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L. Schutzman, Xin Ye, Priti S. Hegde, Misako Nagasaka, Geoffrey R. Oxnard, Ethan S. Sokol, Sai-Hong Ignatius Ou, Zhen Shi
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-14 (2022)
Abstract Recent clinical development of KRAS inhibitors has heightened interest in the genomic landscape of KRAS-altered cancers. We performed a pan-cancer analysis of KRAS-altered samples from 426,706 adult patients with solid or hematologic maligna
Externí odkaz:
https://doaj.org/article/127f5104a768437896be06715f4fd5c4
Autor:
Nicholas J. Bevins, Ryosuke Okamura, Meagan Montesion, Jacob J. Adashek, Aaron M. Goodman, Razelle Kurzrock
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 90-97 (2022)
Introduction: Many studies have focused on the role of programmed death receptor ligand 1 (PD-L1) expression in predicting immunotherapy outcomes. Limited clinical data are available regarding the role of programmed death receptor 1 (PD-1; the PD-L1
Externí odkaz:
https://doaj.org/article/fa7a01e984124b1588d47c75e4aa3a86
Autor:
Radwa Sharaf, Meagan Montesion, Julia F. Hopkins, Jiarong Song, Garrett M. Frampton, Lee A. Albacker
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-15 (2022)
Abstract Background Cancer cells can proliferate indefinitely through telomere maintenance mechanisms. These mechanisms include telomerase-dependent elongation, mediated by TERT activation, and alternative lengthening of telomeres (ALT), linked to lo
Externí odkaz:
https://doaj.org/article/6fb42aa215fa4eadac435596e5d8a55d
Autor:
Jeffrey S Ross, Karthikeyan Murugesan, Meagan Montesion, James Creeden, Lee A Albacker, Andrew D Kelly, Zheng Kuang, Richard S P Huang, Douglas I Lin, Umut Demirci
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Externí odkaz:
https://doaj.org/article/824504b566ee404e875ec16f65f96845
Autor:
Jianhua Zhang, Hao Xu, Alexandre Reuben, Brian Alexander, Jack Lee, Tina Cascone, Jianjun Zhang, Kyle G Mitchell, Marcelo V Negrao, Stephen G Swisher, John V Heymach, Don L Gibbons, Jack A Roth, Ferdinandos Skoulidis, Yasir Y Elamin, Xiuning Le, Anne Tsao, Chang-Jiun Wu, Vincent A Miller, Bonnie S Glisson, Karthikeyan Murugesan, Meagan Montesion, Garrett Frampton, Katja Schulze, Ilze Bara, Vincent Shen, Sylvia Hu, Dawen Sui, Michael E Goldberg, David S Barreto, Jacqulyne P Robichaux, Carl M Gay, Lingzhi Hong, Waree Rinsurongkawong, Vassiliki Papadimitrakopoulou, Gaurav Singal, Lee A Albacker, David Shames
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Non-small cell lung cancer (NSCLC) patients bearing targetable oncogene alterations typically derive limited benefit from immune checkpoint blockade (ICB), which has been attributed to low tumor mutation burden (TMB) and/or PD-L1 levels. W
Externí odkaz:
https://doaj.org/article/deb634044c5641f5a4d7746a8b39b598
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Introduction Several studies have shown clinical outcomes data that support the use of CD274 (PD-L1) copy-number (CN) gains and/or losses as a biomarker for immune checkpoint inhibitor (ICPI). Here, we present the landscape of CD274 CN changes across
Externí odkaz:
https://doaj.org/article/c9754252d8e140ad96c8184de22aa3e4
Autor:
Meagan Montesion, Zachary H. Williams, Ravi P. Subramanian, Charlotte Kuperwasser, John M. Coffin
Publikováno v:
Retrovirology, Vol 15, Iss 1, Pp 1-16 (2018)
Abstract Background Increased transcription of the human endogenous retrovirus group HERV-K (HML-2) is often seen during disease. Although the mechanism of its tissue-specific activation is unclear, research shows that LTR CpG hypomethylation alone i
Externí odkaz:
https://doaj.org/article/723a51c0fff84aaa90972cc669d5a087
Autor:
Smruthy Sivakumar, Jay A. Moore, Meagan Montesion, Radwa Sharaf, Douglas I. Lin, Caterina I. Colon, Zoe Fleischmann, Ericka M. Ebot, Justin Y. Newberg, Jennifer M. Mills, Priti S. Hegde, Quintin Pan, Afshin Dowlati, Garrett M. Frampton, Julien Sage, Christine M. Lovly
Publikováno v:
Cancer Discovery.
Small cell lung cancer (SCLC) is a recalcitrant neuroendocrine carcinoma with dismal survival outcomes. A major barrier in the field has been the relative paucity of human tumors studied. Here we provide an integrated analysis of 3,600 “real-world